BTIG raised the firm’s price target on Insulet (PODD) to $380 from $370 and keeps a Buy rating on the shares after the company’s Investor Day presentation. Insulet aims to be “omnipresent” in type-1 and type-2 diabetes as it targets a “sustained multi-year growth”, the analyst tells investors in a research note. BTIG adds it sees Insulet’s long-range targets as achievable, and the firm is pleased to hear that the company is undertaking various initiatives to drive growth in both the near and long term.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet’s Promising Growth Potential: A Buy Rating Despite Market Skepticism
- Insulet’s Ambitious Growth Targets and Strategic Initiatives Reinforce Buy Rating with Revised Price Target of $380
- Insulet’s Strategic Growth and Innovation Drive ‘Buy’ Rating with $360 Price Target
- Insulet’s Promising Growth: Buy Rating Backed by Strong Sales Projections and Innovation Investment
- Insulet’s Strong Market Position and Growth Prospects Justify Buy Rating